New trial to test potential treatment for chronic kidney disease
Posted:
The first participants have been recruited in Oxford for a new multinational clinical trial that will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD).
Waystar has signed a definitive agreement to acquire Iodine Software, a $1.25 billion deal that seeks to empower healthcare payments with more AI capabilities.
Read more here.
Doctors will be able to prescribe a new treatment for people with inflammatory bowel disease (IBD), after the UK medicines watchdog approved guselkumab (Tremfya) for use on the NHS.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us